15-17 April, 2019

The Waldorf Hilton

London, UK

2018 Speakers


Tuc Ahmad
Scientific Director, Diagnostic Development

Steve Anderson

Clare Balendran
Director & Diagnostic Expert, Precision Medicine

Richard Barker
Co-Founder & CEO
New Medicine Partners

Benoit Canolle
Director, Precision Medicine
Pierre Fabre

Carlos Cara
Head, Medical Immunology International Markets

Kaan Certel
Head of External Innovation, Oncology

Jörg Engelbergs
Scientific Expert Biomedicines
Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines

Jim Godsey
Vice President, R&D
Thermo Fisher Scientific

Jakob Gjørret

Sibylle Hess
Clinical Biomarker Expert, TMED, BCB

Colin Hill
SVP, Commercial Operations

Bob Holt
Director, Biomarkers & Companion Diagnostics
BerGenBio AS

Michael Hummel
Professor & Head of Molecular Pathology

Louis Levy
Director, Corporate & Business Development

Louis Levy began his life science career with Cepton, a strategy consulting boutique for French mid-size biotechs. As a Harvard Blavatnik Fellow, he worked on the commercialization of the Harvard technology conducive to the launch of Ultivue in 2015. Since then, he has spearheaded corporate and business development functions. He is a graduate from the French grande école Telecom Bretagne, with a master’s degree in engineering and from Harvard Business School, with an MBA.

Hugues Malonne
Director General, Post-Authorization

Mirella Marlow
Programme Director, Devices & Diagnostic Systems

Hugh Marston
Senior Research Fellow & Head, Translational Neuroscience
Eli Lilly

Hugh Marston is a senior research fellow leading the Translational Neuroscience Group at Lilly’s Erl Wood research site in Surrey supporting all of Lilly’s active neuroscience programmes. Erl Wood’s research focus covers novel approaches designed to modify neurodegeneration, chronic pain and effective neurosymptomatic intervention. Having originally trained as a psychopharmacologist at Cambridge he has now had nearly 30 years’ experience in various forms of drug discovery research. Most recently as head of pharmacology at IOMet Pharma (pka TPP GD) a virtual pharma company acquired by Merck in 2016.  Prior to that he has lead neuropharmacology teams at Merck, Schering-Plough and Organon working on projects principally in the psychiatry area from discovery through to launch.  As such he has had a long standing interest in transforming our ability to translate science to and from the clinic across the neuroscience disciplines. As part of his role at Lilly he is Project Leader of the IMI2 PRISM initiative an industry/academe EU funded consortium that is seeking to find translatable, quantitative biological phenotypes in CNS disorders.  He maintains an active interest in academic research through collaboration and an honorary professorship at the University of St Andrews with 70+ peer reviewed publications and five granted patents.

Luca Mazzarella
Clinician Scientist, European Institute of Oncology &
Genomics Working Group Leader, Alliance Against Cancer

Dr Luca Mazzarella MD PhD is a clinician scientist at European Institute of Oncology in Milan, where he manages phase 1 trials and numerous translational studies on cancer genomics and epigenomics He obtained his MD in 2004 in Rome, his PhD in Epigenetics in 2010 at Imperial College London and his Board certificate in Medical Oncology at the University of Milan in 2016. He has been awarded numerous research grants and awards as a young investigator, including the Jose Carreras-Young Investigator award from the European Hematology Association in 2014. Since 2016 he coordinates the implementation of nationwide cancer sequencing projects within the Alleanza Contro il Cancro - Genomics working group

Shane McGann
Senior Manager, Regulatory Affairs
Agios Pharmaceuticals

Nicola Normanno
Chief, Cell Biology & Biotherapy Unit & Director, Research Department
INT-Fondazione Pascale

Dr Normanno, MD, earned his Medical Doctor Degree in 1988 at the Medical School, University of Naples (Italy) Federico II. After a residency in oncology at the Oncology Department of the same university, in 1991 he achieved the specialization in medical oncology, and in 2001 in Haematology. Between 1990 and 1993, Dr Normanno did a postdoctoral fellowship at the Tumour Growth Factor Section, Laboratory of Tumour Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. After being senior Investigator and later Acting Chief (2004-2005) at the Experimental Therapy Section, INT-Fondazione Pascale, Naples, Dr Normanno is currently Chief of the Cell Biology and Biotherapy Unit at the same hospital, and since 2006 also Director of the Research Department. Since 1993 Dr Normanno’s area of research has been the study of the role of growth factors and receptors of the EGF family in the pathogenesis of solid tumours; the use of antisense oligonucleotides and inhibitors of receptors in experimental models of molecular therapy of carcinomas; identification of markers of response or resistance to anti-EGFR agents.

Christopher Peters
Clinical Senior Lecturer, Consultant Upper GI & General Surgeon
Imperial College London

Christopher Peters went to medical school in Leeds and after completing basic surgical training moved to Cambridge to carry out a PhD with Professor Rebecca Fitzgerald. During his PhD he developed a four gene signature to predict outcome in oesophageal adenocarcinoma which was validated in 371 independent cases. He also set up the OCCAMS collaboration which went on to be selected to run the International Cancer Genome Consortium's Whole Genome sequencing project in oesophageal adenocarcinoma. OCCAMS has ongoing CRUK funding and has now recruited in excess of 3000 patients. After moving to London to complete his higher surgical training he was appointed as a Clinical Senior Lecturer and Consultant Upper GI surgeon at Imperial College London with a specialist interest in Biomarkers. His academic interest is molecular and clinical predictors of outcome in Oesophageal adenocarcinoma, and in particular developing ways of combining the two to improve stratification of patients. As the Biomarker lead for the NIHR London IVD Co-operative he also has a programme built around trying to better understand which Biomarkers are likely to achieve clinical adoption- aiming to bridge the gap between the millions spent on Biomarker discovery and validation and the handful that achieve clinical success.

Luca Quagliata
Senior Director, Contract R&D Unit Faculty, CAS - Personalized Molecular
Oncology, Senior Consultant, Molecular Pathology Unit, University Hospital Basel

Dr Luca Quagliata is currently serving as Senior Director for the Contract R&D Unit at the Institute of Medical Genetics and Pathology, care of the University Hospital Basel, Switzerland. Dr Quagliata is formally trained in Medical Biotechnology (BSc and MSc both obtained in Italy) with a PhD in Vascular Medicine (Germany) and a Post-Doctoral research activity focused on Liver cancer pathology (Switzerland). Throughout these different (research and diagnostics) international working experiences, he gained extensive expertise in the field of Molecular Oncology. After joining the National Institute of Health (NIH, USA), Dr Quagliata moved back to Switzerland and took over the leadership of the Molecular Diagnostics Team at the Institute of Medical Genetics and Pathology in Basel. With the ultimate goal of enabling Precision Medicine, Dr Quagliata’s Team has been among the first in Europe introducing Next Generation Sequencing (NGS) in the routine Molecular Diagnostics of Solid Tumours. Nowadays, NGS in Basel is as well used to analyse Liquid Biopsy specimens. The Molecular Diagnostics Unit represents the largest hospital-based provider of diagnostic sequencing services in Switzerland with thousands of samples analysed within the last years, and hundreds of Liquid Biopsies, serving both public institutions (e.g. Hospitals) and private corporations (e.g. Pharmaceutical companies). More recently, Dr Quagliata has been appointed as Faculty member and responsible of the Molecular Pathology curricula for the CAS - Certificate of Advanced Study in Personalized Molecular Oncology at the Faculty of Medicine, University of Basel.

Mark Roberts
Senior Director, Diagnostics Development

Dieter Schönwald
Global Technical Officer, IVD

Simon Shohet
Senior Director, Market Access & Pricing

John Simmons
Director, Translational Science & Diagnostics
Personal Genome Diagnostics

Dominic Smethurst
Tusk Therapeutics

Andreas Stange
Vice President MHS, Global IVD

Dr. Julia Stevens
Senior Scientist

Dr Julia Stevens graduated from the University of Newcastle upon Tyne with a BSc Hons in microbiology. She was awarded a PhD in cellular microbiology by University College London and went on to work at Imperial College, London as a PostDoctoral Research Assistant, on the development of Group B meningococcal vaccines. Julia joined Asterand (a BioIVT company) in 2004 as a Scientist in the department of Exploratory Drug Profiling, before joining the Molecular Pathology group in 2006. She is currently a Senior Scientist in the Group and a trained Study Director for Regulatory Studies in IHC.

Kristin Stieler
Technical & Clinical Product Lead – Europe
Sysmex Inostics

Farhat Syed
Associate Director, Precision Medicine

Tom Turi
Vice President, Companion Diagnostics

Caoimhe Vallely-Gilroy
Director & Head, Clinical Trials Biosample Management
Merck KGaA

Steven Walker
Head of Internal Product Management
Almac Diagnostics

Dr Steven Walker heads the internal product management activities at Almac Diagnostics.  Specifically this includes the development of internal discovery of biomarker assays towards commercialisation as a diagnostic test delivered directly from Almac CLIA and CAP accredited laboratories, or as a companion diagnostic test for in partnership with Pharma / Biopharma. Steven studied at the University of Dundee, leading to a PhD before postgraduate work at the Beatson Cancer Research UK Institute in Glasgow. He joined Almac Diagnostics in 2005, initially as a Senior Scientist, then as Team Leader and then Research Manager before taking the role in Product Development. As part of his time with the research team, he was involved in the discovery and development of several of the internally discovered biomarker assays.

John Wise
Pistoia Alliance

John Wise MA is a Consultant at the Pistoia Alliance and specialises in the coordination of pre-competitive alliances in life science R&D. The Pistoia Alliance, a not-for-profit, members’ organisation committed to lowering the barriers to innovation in life science R&D. John is also the Programme Coordinator for the PRISME Forum, a not-for-profit biopharma R&D IT / Informatics leadership group focused on the identification of “hot topics” and the sharing of biopharma R&D IT / Informatics best practices. Previously, John has held Informatics leadership roles in a variety of organizations including the University of London, Sandoz, the Imperial Cancer Research Fund (now CRUK), Roche, Ipsen and Daiichi Sankyo. John has also worked in the technology supplier side of the industry.  These roles have allowed John to gain direct hands-on experience of delivering computer-based services to life science R&D in general and in particular to the discovery, non-clinical development, clinical development and regulatory affairs domains of the pharmaceutical industry. John has frequently presented at conferences, chaired panel and roundtable discussion, and has written articles for various journals. He is committed to encouraging Pharma to get out of the IT business and instead use expert, third-party, cost-effective, regulatory-compliant, hosted information services.

Alan Wookey
Scientific Advisor, Oncology and Companion Diagnostics
Q2 Solutions